1. Screening for Pharmaceutical Trials
Ophthalytics facilitates the screening for pharmaceutical trials by leveraging advanced AI technology to enhance the accuracy and efficiency of participant selection based on ophthalmic criteria.
2. Adding revenue streams for Primary Care Physicians
Upon receiving FDA clearance for Ophthal-360, primary care physicians will be able to add a new revenue source through screening for diabetic retinopathy.
3. Enhancing existing screening services
Increase the efficiency of current screening systems by 3x and beyond with either our Clearview-360 AI assistance or Ophthal-360 autonomous AI.
Ophthalytics products revolutionize the ophthalmology industry by leveraging advanced AI technology to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes.
Rapidly and cost-effectively screen for upcoming drug trials or unlock precise diagnoses and enhance the development of ophthalmic treatments and therapies.
3. Endocrinologists / Diabetologists
Patients with vision-threatening retinopathy can be identified in the clinic in real-time by an endocrinologist or diabetologist, so they can be referred to an eye specialist to save their vision.
4. Medical Schools
Advanced teaching and learning opportunities are available to prepare students for the future of diagnostic technology.
5. Nurses & Educators
- Improve patient care by utilizing Ophthalytics AI Eye Screening for diabetic retinopathy screening without the need for an on-site eye care doctor.
- Create an educational platform for diabetic patients to learn about eye disease, its treatment, and the benefits of diabetic retinopathy screening.
6. Remote Eye Clinic (Rural Areas)
Ophthalytics provides access to complementary technology for developing and third-world countries, ensuring that limited access to eye specialists will not be an issue with this service. Eye technicians can operate this system efficiently and refer patients entirely remotely.
7. Device Manufactures
Manufacturers of fundus machines can integrate our software into their continuity plans to detect Diabetic Retinopathy independently.
IMPROVING HEALTH EQUITY
At Ophthalytics, we are dedicated to improving health equity and ensuring that underserved communities have access to life-changing eye care. One of our key initiatives is providing free diabetic retinopathy scans through our advanced AI retinal screening technology. By offering efficient and accurate diagnostic capabilities, we aim to identify diabetic retinopathy early on, enabling timely intervention and preventing vision loss.
Our AI-powered diabetic retinopathy scan is a game-changer in diabetic eye exams. By leveraging the capabilities of artificial intelligence, we have developed a cutting-edge solution that streamlines the screening process, making it more accessible and cost-effective. Our technology is specifically designed to detect signs of diabetic retinopathy, enabling healthcare providers to intervene at the earliest stages of the disease and improve patient outcomes.
We understand the importance of reaching underserved communities and have actively partnered with organizations to expand our impact. Through collaborations with The Diabetes Centre and the Layton Rahmatulla Benevolent Trust (LRBT), we are extending the reach of our services to rural and marginalized populations in Pakistan. By leveraging our AI retinal screening technology, we can overcome barriers to access and ensure that individuals in underserved communities receive the diabetic eye exams they deserve.
With our focus on health equity and our commitment to leveraging technology for social good, Ophthalytics is transforming the landscape of eye care. Our diabetic retinopathy scan, powered by AI, not only improves the efficiency and accuracy of screenings but also contributes to reducing disparities in healthcare access. Join us in our mission to make a positive impact on the lives of individuals in underserved communities by embracing the potential of AI retinal screening and diabetic eye exams.
PREVENTING BLINDNESS DETECTING THE UNDETECTABLE
OPHTHALYTICS – THE LARGEST AI-POWERED EYE DISEASE PLATFORM